Reprogramming of pancreatic exocrine cells into cells resembling beta cells may provide a strategy for treating diabetes. Here we show that transient administration of epidermal growth factor and ciliary neurotrophic factor to adult mice with chronic hyperglycemia efficiently stimulates the conversion of terminally differentiated acinar cells to beta-like cells. Newly generated beta-like cells are epigenetically reprogrammed, functional and glucose responsive, and they reinstate normal glycemic control for up to 248 d. The regenerative process depends on Stat3 signaling and requires a threshold number of Neurogenin 3 (Ngn3)-expressing acinar cells. In contrast to previous work demonstrating in vivo conversion of acinar cells to beta-like cells by viral delivery of exogenous transcription factors, our approach achieves acinar-to-beta-cell reprogramming through transient cytokine exposure rather than genetic modification.
A r t i c l e s
The potential to regenerate severely damaged tissue by converting one differentiated cell type to another is common in lower vertebrates 1 , but in mammals this conversion capacity is rare and mainly associated with pathological metaplasia 2 . Thus, the discovery of signaling pathways capable of inducing therapeutic cellular plasticity could open new avenues in regenerative medicine 3, 4 . Insufficient functional beta cell mass causes diabetes, a metabolic disorder with clinical complications arising from chronically elevated blood glucose levels. One potential treatment for this disease would be direct conversion of pancreatic non-beta cells into beta cells in sufficient numbers to restore and maintain a normal concentration of sugar in the blood (normoglycemia). The capacity of other adult pancreatic cell types to give rise to new beta cells remains unclear. Genetic lineage tracing in mice demonstrated that under conditions of normal physiology or modest beta cell damage, pre-existing beta cells are solely responsible for generation of new beta cells by self-duplication 5, 6 . But with extensive tissue damage by surgical duct ligation, facultative progenitor cells located near the lining of exocrine duct structures are activated to differentiate into new beta cells 7 . Nevertheless, a duct-related origin of these progenitor cells was contradicted by recent reports using genetic lineage tracing with different duct-specific promoters [8] [9] [10] [11] [12] . Other work showed that after toxin-induced ablation of the near-total beta cell mass, alpha cells were reprogrammed to new beta cells 13 .
The possibility of converting acinar cells to beta cells was suggested in a study in which diabetic mice were treated with epidermal growth factor (EGF) and gastrin 14 . However, this study lacked genetic lineage tracing evidence, and subsequent genetic lineage tracing in mice did not support an acinar cell origin of beta cells in several regenerative settings in the injured adult pancreas 15 . In a notable advance, transduction of mouse acinar cells in vivo with vectors encoding three transcription factors that are necessary for beta cell development induced direct conversion of acinar cells to functional beta-like cells 16 . Further supporting the notion of lineage plasticity of acinar cells, rodent acinar cells can adopt a duct-like phenotype following suspension culture [17] [18] [19] , dexamethasone treatment can induce their transdifferentiation to a hepatocyte-like cell 20 , and addition of EGF in combination with nicotinamide, leukemia inhibitory factor (LIF) or ciliary neurotrophic factor (CNTF) can stimulate their reprogramming into insulin-positive cells (refs. 21-24 and unpublished data). However, the capacity to reprogram acinar cells to beta cells in vivo without genetic manipulation has not been demonstrated.
Given that EGF in combination with either LIF or CNTF can reprogram rat acinar cells into insulin-producing beta-like cells in vitro [21] [22] [23] , we tested the capacity of EGF and CNTF to induce beta cell regeneration in diabetic mice. We show that this therapy regenerates a functional beta cell mass sufficient to normalize hyperglycemia and transient cytokine treatment induces acinar cell reprogramming and regenerates functional beta cell mass in diabetic mice A r t i c l e s maintain normoglycemia for at least 248 d. The regenerative process involves reprogramming of acinar cells and depends on activation of the pro-endocrine regulator gene Ngn3 and signaling through Stat3. These results and this experimental model may aid future studies of the potential for using pharmacologic manipulation of signaling pathways as a therapy for diabetes.
RESULTS

EGF and CNTF restore normoglycemia
We administered EGF and CNTF treatment to 13-week-old mice that had been hyperglycemic for 5 weeks. Hyperglycemia was induced by intravenous (i.v.) injection of a single dose of the betacell toxin alloxan 25 . All alloxan-treated mice (n = 70) displayed a sharp increase in blood sugar concentrations and these concentrations remained >25 mmol/l (Fig. 1a) . Five weeks after alloxan injection, mini-osmotic pumps were implanted into the peritoneum to deliver either EGF and CNTF or vehicle. At the time of pump implantation the average glycemia was 32.8 ± 2.7 mmol/l in alloxantreated mice (n = 70; referred to as ALX 35d ) compared to 5.4 ± 0.4 mmol/l in control mice with normoglycemia (NG 35d ) (n = 10; P < 0.01). These pumps released their contents at a constant flux rate over a 7-d period. Of all ALX 35d mice implanted with cytokine-releasing pumps (n = 35; referred to as ALX 35d/CK ) 64.7 ± 2.1% responded to the cytokine mix and had glycemia lower than 14 mmol/l; these responsive mice henceforth are referred to as ALX 35d/CK resp . In contrast, cytokine-unresponsive mice (referred to as ALX 35d/CK unresp ) remained hyperglycemic, as did ALX 35d mice implanted with control pumps (referred to as ALX 35d/CTR ). The cytokine combination did not affect the blood sugar levels of normoglycemic mice (Fig. 1a) . ALX 35d/CK resp mice were, on average, more glucose tolerant than ALX 35d/CTR mice (Fig. 1b) , but their blood glucose remained higher than that in NG 35d/CTR mice. All animals were insulin sensitive, but ALX 35d/CK resp mice were more sensitive than NG 35d/CTR mice (Fig. 1c) (Fig. 1h) , 1-way ANOVA (Fig. 1f) , 2-way ANOVA with Bonferroni post-hoc test (Fig. 1d,g,i) or a Linear Mixed Effects Model (Fig. 1b,c,e) . 
r e t r a c t e d a r t i c l e
A r t i c l e s
The body weights of both ALX 35d/CK and ALX 35d/CTR mice were lower than those of NG 35d/CK and NG 35d/CTR mice, but the difference became statistically significant only after pump implantation (P < 0.05) (Fig. 1d) . ALX 35d/CTR mice remained severely hyperglycemic and eventually died, whereas ALX 35d/CK resp mice were normoglycemic for at least 248 d after cytokine release (Supplementary Fig. 1a) , and during this time the gain of body weight by these responsive mice paralleled that in normoglycemic control mice ( Supplementary  Fig. 1b) . At the end of the 7-d cytokine release, the ratio of lean over fat mass was higher in ALX 35d compared to NG 35d mice (Supplementary Fig. 1c) .
Pancreas insulin content (Fig. 1e) and serum insulin levels (both in fasted and glucose-stimulated animals) (Fig. 1f) significantly increased in ALX 35d/CK compared with ALX 35d/CTR mice (P < 0.01), but were still lower than in NG 35d/CTR mice. Serum glucagon levels were similar in all groups of mice (Supplementary Fig. 1d) . Notably, islets isolated from NG 35d/CTR and ALX 35d/CK mice secreted similar amounts of insulin after glucose stimulation (Fig. 1g) .
Treatment with either EGF or CNTF alone did not induce normoglycemia ( Supplementary Fig. 1e,f) . However, the combination of EGF and CNTF also improved glycemia and body weight in a second model of diabetes in which beta cell destruction was induced by streptozotocin (STZ), but at 50% lower efficiency than when hyperglycemia was induced by ALX (33.3 ± 1.5% of STZ 35d/CK mice showed markedly decreased glycemia by day 7 of treatment (n = 15) and glycemia remained stable in the responsive mice for at least 72 d). The effect of cytokine treatment is thus less impressive in STZ-treated mice, possibly because they had slightly lower glycemia than ALX-treated mice before pump implantation ( Supplementary Fig. 1g,h) .
After ALX-mediated beta cell destruction, the fraction of insulin + cells in tissue sections of pancreas from ALX 35d/CTR and ALX 35d/CK unresp mice remained similar (P > 0.05; n = 6), but ALX 35d/CK resp mice had an increase of such cells starting on day 39 (4 d after pump implantation) (P < 0.05; n = 6), albeit not to the same level observed in NG 35d/CTR mice (P < 0.01; n = 6) (Fig. 1h) . We also measured insulin + cell mass by morphometry at various time points after ALX injection. The ratio of insulin + area to the total area of the pancreas tissue section was highest in NG CTR mice at all time points and significantly increased in ALX 35d/CK resp mice starting on day 42 ( Supplementary Fig. 1i ).
We observed actively cycling beta cells at various time points after ALX treatment. The fraction of insulin + cells that expressed Ki67 was highest in NG 35d/CTR mice at all time points (P < 0.01; n = 6), remained equally low in ALX 35d/CTR and ALX 35d/CK unresp mice (P > 0.05; n = 6), and increased to a statistically significant extent in ALX 35d/CK resp mice starting at day 42 (P < 0.05; n = 6) ( Supplementary  Fig. 1j,k) . In contrast, cumulative DNA synthesis by beta cells, measured as the fraction of IdU + insulin + cells, was highest in ALX 35d/CK resp mice (P < 0.05; n = 4) ( Supplementary Fig. 1l ,m). These data provide evidence of a modest increase in beta cell replication in ALX 35d/CK resp mice, especially toward the end of cytokine treatment and justified a search for the origin of the newly formed beta-like cells by lineage tracing.
Acinar cell origin of beta-like cells
To elucidate the origin of the newly formed insulin-expressing cells in ALX 35d/CK mice, we used genetic lineage tracing; more specifically, we tracked insulin-expressing beta cells, elastase-expressing acinar cells and HNF1b-expressing duct cells. For example, we used Rip CreERT R26 LacZ mice 5 in which, after tamoxifen injection, Cre expression is activated, which, in turn, induces expression of lacZ, which encodes β-galactosidase. As a result, cells that exhibited insulin promoter activity at some point during their existence can be marked by X-gal staining, which detects β-galactosidase. In these experiments, tracer mice were injected with tamoxifen followed by a 24-d period of tamoxifen washout, followed by 35 d of hyperglycemia (Fig. 2a) . The majority of pancreas cells that express Pdx1, a beta cellspecific marker, in NG 35d/CTR and ALX 35d/CTR Rip CreERT R26 LacZ mice showed X-gal reactivity (81.5 ± 2.5%; n = 12, and 84.3 ± 3.8%; n = 12, respectively) (Fig. 2b,c) . We stained for Pdx1 rather than insulin to avoid omitting beta cells that had degranulated during hyperglycemia. However, in ALX 35d/CK mice only 7.2 ± 0.9% (n = 12; P < 0.01) of the Pdx1 + cells were X-gal reactive. These data indicate that the population of beta cells that were labeled before cytokine treatment was strongly diluted after treatment, suggesting that new beta-like cells originated from non-beta cells.
The possible contribution of duct cells to newly formed insulin + cells was determined in Hnf1b CreERT R26 LacZ tracer mice in which the HNF1b promoter is specifically expressed in duct cells 8 . In both ALX 35d/CTR and ALX 35d/CK mice, 19% of all duct cells expressed the reporter (Supplementary Fig. 2a,b) . In ALX 35d/CK mice, 1.1 ± 0.5% of beta-like cells were stained by X-gal + , a small but significantly higher fraction than the 0.4 ± 0.4% X-gal + beta cells found in ALX 35d/CTR mice (n = 12 in each experimental group, P < 0.05). These results therefore suggest that the number of beta-like cells derived from duct cells in ALX 35d/CK mice was too low to account for the observed total increase in beta-like cells.
Acinar cells were labeled in Ela CreERT R26 LacZ mice 19 (Ela denotes elastase, a marker of acinar cells) with a recombination efficiency of 45% in ALX 35d/CTR and ALX 35d/CK mice (Fig. 2e) . In ALX 35d/CK Ela CreERT R26 LacZ mice, 32.1 ± 2.1% of insulin + cells were X-gal + (Fig. 2d,e) , whereas only 1.0 ± 0.5% of insulin + cells were X-gal + in ALX 35d/CTR mice (n = 13; P < 0.01). Of the total number of X-gal + cells, 0.02 ± 0.01% were insulin + in ALX 35d/CTR mice and 3.0 ± 0.4% were insulin + in ALX 35d/CK mice (n = 13; P < 0.01). To validate these remarkable findings we used Ptf1a CreERT R26 YFP mice as an alternative approach for tracing the lineage of acinar cell-derived descendants 26 ( Supplementary Fig. 3a) ; these mice showed an overall recombination efficiency of 50% of acinar cells in all experimental groups (Supplementary Fig. 3b ). Four days after pump implantation, pancreases of Ptf1a CreERT R26 YFP mice contained small clusters of 3.4 ± 0.6 insulin + cells dispersed within the parenchyma, many of which were YFP + and thus derived from acinar cells (Supplementary Fig. 3c ). The average number of beta-like cells per cluster was significantly increased at day 7 after pump implantation (35.2 ± 4.6 insulin + cells/ cluster; n = 25; P < 0.01) but was significantly lower than in NG 35d/CTR mice (69.8 ± 7.0 cells/cluster). At this time point, YFP was expressed in 43.1 ± 3.5% of insulin + cells of Ptf1a CreERT R26 YFP ALX 35d/CK mice (n = 12), compared with 1.0 ± 0.7% of insulin + cells in ALX 35d/CTR mice (n = 12; P < 0.001). In NG 35d/CTR animals, only 0.2 ± 0.1% of insulin + cells co-expressed YFP (Supplementary Fig. 3b ). These results indicate that the majority of newly formed beta-like cells in ALX 35d/CK mice originated from elastase + Ptf1a + acinar cells.
We sorted (i) new beta-like cells derived from acinar cells, (ii) normal beta cells and (iii) normal acinar cells from Ptf1a CreERT R26 YFP NG 35d/CTR and ALX 35d/CK mice by flow cytometry ( Supplementary  Fig. 3d ) and compared the DNA methylation at the beta cell-specific insulin and GLUT2 promoters and at the acinar cell-specific Amy2b promoter. Insulin and GLUT2 promoter DNA was hypomethylated at CpG sequences in normal beta cells and acinar cell-derived betalike cells, whereas these beta cell-specific promoters were markedly hypermethylated in acinar cells. The acinar cell-specific Amy2b A r t i c l e s promoter was hypomethylated in acinar cells but strongly methylated in acinar cell-derived beta-like cells (Supplementary Fig. 3e ).
Ngn3 in acinar-to-beta reprogramming Cytokine-induced reprogramming of rat acinar cells into beta-like cells requires re-expression of Neurogenin-3 (Ngn3) 22 , a bHLH transcription factor required for islet cell formation during embryonic development. Therefore, we examined Ngn3 expression in the pancreas of cytokine-treated diabetic mice. We detected an increase in Ngn3 expression in ALX 35d/CK compared with ALX 35d/CTR and NG 35d/CTR mice (Supplementary Fig. 4a ). Next we used Ngn3 YFP (knock-add-on) mice, in which YFP is inserted in the 3′ untranslated region of the Ngn3 locus 27 , to identify YFP + cells on pancreas sections. YFP + cells were dispersed over the exocrine and endocrine compartments of the pancreas in ALX 35d/CK but not in ALX 35d/CTR mice (Fig. 3a-c) . The majority of the YFP + cells also expressed amylase, (176 ± 31 amylase + YFP + cells per 10 5 pancreas cells counted, representing 84.5 ± 7.8% of all YFP + cells), and some expressed insulin (10 ± 2 insulin + YFP + cells per 10 5 pancreas cells counted, representing 9.2 ± 1.7% of all YFP + cells; n = 15). 1.6 ± 0.3% (n = 15) of acinar cells expressed YFP (Fig. 3b) , and 5.1 ± 0.6% (n = 15) of beta cells expressed YFP (Fig. 3c) . Of all YFP + cells, 27.1 ± 2.8% still expressed the Ngn3 protein and all YFP + cells showed a strong immune reactivity for Pdx1, regardless of their location (Fig. 3d) . These observations are consistent with a model in which Ngn3 + cells appear within the exocrine parenchyma of ALX 35d/CK mice, cluster together and eventually stop expressing YFP as insulin protein becomes detectable.
We isolated undifferentiated potential progenitors of beta cells from Ngn3 YFP mice by flow cytometric sorting of cells that express YFP (Fig. 3e) . From the pancreas of ALX 35d/CK resp mice we isolated 14,322 ± 1,235 YFP + cells (Fig. 3f) . Only 1,968 ± 243 YFP + cells were isolated from ALX 35d/CK unresp mice and 178 ± 19 from NG 35d/CTR mice (n = 15; P < 0.01) (Fig. 3f) . Although based on correlation, these findings suggest that the number of Ngn3 + cells may determine the threshold for a successful regenerative process.
From the pancreas of ALX 35d/CK mice, we isolated 46,587 ± 417 YFP − cells that also showed high sideward scatter (SSC high ) and stained with 6-methoxy-8-p-toluenesulfonamido-quinoline (TSQ), a zinc-chelating near-UV fluorophore that labels granulated beta cells 7 ; in comparison we isolated 694 ± 143 such cells from ALX 35d/CTR mice and 94,261 ± 566 from NG 35d/CTR mice (Fig. 3g) . Of YFP + SSC low TSQ − cells sorted from ALX 35d/CK resp mice, 87% stained positive for YFP (using a YFP-specific antibody), 23% stained positive for Ngn3 and only 3% stained positive for insulin (Fig. 3h) . 
r e t r a c t e d a r t i c l e
A r t i c l e s YFP − SSC high TSQ + cells from ALX 35d/CK resp mice were 61% insulin + and, as expected, represent the granulated, differentiated endocrine cell pool (Fig. 3h) (Fig. 3b) , 2-way ANOVA with Bonferroni post-hoc test (Fig. 3g,h ). Scale bars, 40 µm (a,d,h). (Fig. 4b,c) . Scale bars, 10 µm (a). 
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A r t i c l e s two cell fractions (Supplementary Fig. 4b ).
The elevated number of YFP − SSC high TSQ + differentiated cells in ALX 35d/CK mice is consistent with their lowered blood glucose level, improved glucose tolerance and increased number of beta-like cells. We next used genetic lineage tracing to assess whether newly formed insulin + cells previously expressed Ngn3. Specifically, the Ngn3 + cell lineage was permanently traced in Ngn3 CreERT R26 YFP mice that were injected with tamoxifen at day −2, 0, 2, 4 and 6, with day 0 the day of pump implantation. YFP expression was subsequently examined to identify cells that originated from Ngn3 + cells during the cytokine treatment (Fig. 4a) . YFP was present in a small percentage of insulin + or amylase + cells in ALX 35d/CTR , NG 35d/CTR and ALX 35d/CK unresp mice (Fig. 4b,c) . In contrast, ALX 35d/CK resp pancreases (ten mice analyzed) contained 2.8 ± 0.4 clusters of amylase + YFP + insulin − cells per section, and 89.8 ± 1.4% of insulin + cells were YFP + (Fig. 4b,c) . Notably, few alpha cells expressed YFP, suggesting that Ngn3 + cells only marginally contributed to the alpha cell population (<3% in all conditions tested) (Supplementary Fig. 5a,b) . Together with the acinar cell lineage tracing, these results indicate that most beta-like cells in EGF-and CNTF-treated diabetic mice derived from Ngn3-expressing acinar cells.
To examine whether acinar to beta-like cell conversion in ALX 35d/CK mice requires Ngn3, we inactivated the Ngn3 gene in acinar cells of Ptf1a CreERT R26 YFP Ngn3 lox/lox mice by tamoxifen treatment before injection of ALX. As expected, tamoxifen treatment induced YFP labeling (indicating Cre-mediated recombination) in ~50% of acinar cells in all mice regardless of ALX and pump treatment (Supplementary Fig. 6a,d) . In ALX 35d/CK mice the number of YFP + beta-like cells was markedly decreased in animals that deleted two Ngn3 alleles (P < 0.01) (Supplementary Fig. 6b) . Furthermore, the total number of beta-like cells (both YFP + and YFP − ) in the pancreases of tamoxifen-treated ALX 35d/CK Ptf1a CreERT R26 YFP Ngn3 lox/lox mice was reduced by approximately half (P < 0.01) ( Supplementary  Fig. 6c,d) . Because R26 YFP and Ngn3 lox/lox recombination occurs in the same acinar cells, the 50% recombination efficiency of Ptf1a CreERT mice (Supplementary Fig. 6a ), in combination with the 94% reduction in beta-like cell reprogramming of recombined acinar cells lacking Ngn3 (Supplementary Fig. 6b) , explains the magnitude of the reduction in total beta-like cells (Supplementary Fig. 6c,d ). In accordance with these findings, blood glucose levels in ALX 35d/CK mice with acinar-specific loss of Ngn3 were significantly higher than those in ALX 35d/CK mice (n = 4; P < 0.05) (Supplementary Fig. 6e ). Taken together, these results demonstrate that acinar-to-beta reprogramming in this model requires the pro-endocrine regulator Ngn3.
Stat3 in acinar-to-beta reprogramming
To identify the pancreatic cell types that act as primary targets of CNTF in ALX 35d/CK mice, we measured CNTF signaling by analyzing phosphorylation of Stat3. In pancreases of ALX 35d/CK resp mice, activated Stat3 (phospho-Stat3) was detected in the nuclei of 53.2 ± 7.8% of extraislet (mainly acinar) and 76.6 ± 4.9% of islet cells (n = 10) (Fig. 5a) . The level of phospho-Stat3 staining was highest in the islet cells. In contrast, activated Stat3 was absent from the pancreas of NG 35d/CTR , ALX 35d/CTR and ALX 35d/CK unresp mice (n = 10) (Fig. 5a) . Using Ptf1a CreERT R26 YFP mice, we demonstrated expression of phospho-Stat3 in both acinar cells and newly formed beta-like cells (Fig. 5b) . (Fig. 5c) , suggesting a requirement for CNTF signaling directly in acinar cells. Moreover, in ALX 35d/CK mice with an acinar-specific excision of Stat3, the number of YFP + insulin + cells was markedly decreased (n = 10; P < 0.01) (Fig. 5d) . Both the expression pattern of phospho-Stat3 and the effect of acinar cellspecific knockout of Stat3 indicate that CNTF signals through Stat3 in acinar cells to initiate their reprogramming to beta-like cells.
r e t r a c t e d a r t i c l e
A r t i c l e s Excision of Stat3 in pre-existing acinar cells
DISCUSSION
Here we demonstrate that a combination of the cytokines EGF and CNTF can reverse chemically induced diabetes in young adult mice that have been hyperglycemic for 35 d. Cytokine-treated mice showing normalized glycemia also showed a marked increase in beta cell mass and pancreas insulin content, and their newly formed betalike cells were glucose responsive. Restoration of beta cell mass and normoglycemia resulted mainly from conversion of differentiated acinar cells to functional beta-like cells; acinar-to-beta reprogramming produced 39.1 ± 8.2% of the original number of beta cells, whereas other sources, including pre-existing beta and duct cells, contributed an additional 4%. As the restored normoglycemia was durable, cytokine-induced reprogramming of acinar cells generates a lasting population of functional beta-like cells.
Compared with the previous report on reprogramming of acinar cells with adenoviruses expressing islet transcription factors 16 , our strategy avoids the use of viruses and their associated risks. Moreover, our results contrast with previous reports showing that acinar cells do not spontaneously contribute to neoformation of beta cells after partial duct ligation, partial pancreatectomy or caerulein-induced pancreatitis 15 . In addition, although treatment with EGF and gastrin starting 24 h after ALX-mediated induction of hyperglycemia was reported to restore normoglycemia 14 , our own unpublished data indicate that EGF and gastrin failed to ameliorate the long-term hyperglycemia in ALX 35d mice, possibly because this combination of cytokines acts solely by protecting residual beta cells as it neither activated Ngn3 gene expression nor induced acinar-to-beta-cell reprogramming.
The present study sheds light on the actions of EGF and CNTF in the pancreas. Mice with targeted inactivation of EGF show no pancreatic abnormalities, possibly owing to the expression of other ErbB ligands that may act in a redundant manner 28 . In the adult mouse pancreas, islet and duct cells express the EGF receptor, but acinar cells do not 29 . CNTF is expressed by pancreatic beta cells 30 , and we detected CNTFRα, a component of its receptor, in acinar and duct cells (data not shown). CNTF signals through the heterotrimer of CNTFRα, LIF receptor beta and gp130 (refs. 31,32) , induces weight loss in rodents 33, 34 and improves insulin sensitivity in models of type II diabetes eventually leading to a correction of hyperglycemia 35, 36 . Accordingly, an effect of CNTF on insulin action may explain why we observed near normoglycemia despite only 40%, rather than complete, regeneration of the beta cell mass in ALX 35d/CK resp mice. CNTF also acts directly on beta cells to attenuate insulin release and to block interleukin 1β-mediated beta cell death (through Stat3-SOCS3 signaling) 37, 38 . However, genetic lineage tracing of pre-existing and cycling beta cells indicated that direct effects of CNTF on beta cells could account for only about 10% of all recovered insulin + cells in ALX 35d/CK mice.
We observed a positive correlation between activation of Stat3 and normalization of hyperglycemia in response to cytokine treatment. Both EGF and CNTF are reported to signal through Stat3 (ref. 39 ), although treatment with EGF or CNTF did not independently restore normoglycemia. In addition, selective removal of Stat3 from preexisting acinar cells prevented a correction of blood glucose levels as well as cytokine-induced reprogramming of acinar cells to beta-like cells. As Stat3 activation after cytokine treatment was similar in all of the different strains studied, the cytokine effects in this experimental model are independent of mouse strain.
EGF and CNTF treatment of hypoglycemic mice activated expression of the pro-endocrine embryonic transcription factor Ngn3 (refs. 40,41) . YFP + cells were dispersed throughout the acinar cell compartment of the pancreas from ALX 35d/CK Ngn3 YFP mice and were tenfold more numerous than Ngn3 YFP cells induced by partial duct ligation 7 . A correlation between the number of YFP + cells in the pancreas of long-term diabetic Ngn3 YFP mice and the responsiveness of these mice to the cytokine treatment suggests that a minimal number of Ngn3 + cells is necessary to drive beta cell regeneration; in ALX 35d/CK unresp mice the number of Ngn3 + cells, possibly in addition to the abundance of Ngn3 in each cell, may be below this putative threshold.
The link between activation of Ngn3 gene expression in facultative progenitor cells and adult beta cell formation, however, remains controversial as beta cells per se produce low levels of Ngn3 (ref. 42) . Permanent genetic lineage tracing of Ngn3 + cells revealed that the majority of newly formed insulin + cells in ALX 35d/CK resp mice derived from Ngn3-expressing acinar cells. In addition to the low beta cell cycle activity, the lineage-tracing data also suggest that migration, rather than division, of beta-like cells is a primary event during islet formation in our model. Indeed, whereas generation of new, small, islet-like clusters was already observed only 4 d after EGF and CNTF treatment, large islets were already observed at day 7. The observation that alpha cells were dispersed over the new islets rather than at their periphery supports continuous migration of new beta-like cells to islet remnants rather than fission of small islets. In our model YFP was detected in only a very small number of the endocrine beta cells on pancreas tissue sections of NG CTR and ALX CTR mice, and Ngn3-encoding transcripts were barely detectable in granulated endocrine islet cells isolated from ALX 35d/CK mice; together, these observations suggest a minor role for Ngn3 expression in beta cells in our model. However, when Ngn3 expression was deleted specifically from acinar cells before the cytokine treatment, ALX 35d/CK mice remained more hyperglycemic and the number of newly formed insulin + cells was markedly decreased relative to Ngn3 wild-type mice. Therefore, activation of Ngn3 gene expression is required for the complete transdifferentiation of acinar cells to betalike cells.
The regenerative process observed here may be compared to other examples of directed adult tissue regeneration. For example, postnatal mammalian digit regeneration may occur through BMP-dependent signaling 43, 44 to tissue resident stem cells rather than through activation of pluripotent blastema cells as seen in amphibian limb regeneration 45 . Specifically, fate-restricted progenitors could be marked by Msx1 expression and represent a conserved cellular mode for mammalian regeneration 46, 47 . Despite these previous reports of extreme tissue regeneration in mammals 44, 47 , the mammalian capacity for tissue regeneration by cellular reprogramming or transdifferentiation remains unclear. Nevertheless, our data demonstrate that pharmacologic treatment can promote clinically meaningful plasticity in the pancreas in live adult mice. This model may be used to study the signaling pathways involved in acinar-to-beta-like cell reprogramming, and to identify additional compounds and targets that may promote this process in a therapeutic setting. 
